+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Recombinant Human Erythropoietin Treatment in Uremic Patients on Oxygen Affinity of Hemoglobin

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Anemia of chronic renal failure is associated with a reduced affinity of hemoglobin for oxygen (Hb-O<sub>2</sub> affinity). It has been reported that the correction of renal anemia by recombinant human erythropoietin (rhuEPO) treatment could be associated paradoxically with a further decrease in Hb-O<sub>2</sub> affinity. We investigated changes in the compensatory mechanisms of chronic renal anemia during 25 weeks of rhuEPO treatment, in 19 chronic hemodialyzed (HD) patients. There was no significant variation of mean standard P<sub>50</sub> (P<sub>50</sub>std). Average 2,3-diphos-phoglycerate (DPG) increased after 13 weeks and remained stable. The large interindividual variations prompted us to study ΔP<sub>50</sub>std and ΔHb. We demonstrated a negative correlation between ΔP<sub>50</sub>std and ΔHb. Thus, P<sub>50</sub>std increased in patients who did not immediately correct their anemia and decreased in patients whose Hb values rose. These data showed that the major factor influencing variations of Hb-O<sub>2</sub> affinity in chronic HD patients treated by rhuEPO is the variation of Hb concentrations. In our study, it was demonstrated that the most important rise in P<sub>50</sub>std and 2,3-DPG occurred in patients who were late responders to rhuEPO.

          Related collections

          Author and article information

          S. Karger AG
          16 December 2008
          : 66
          : 2
          : 147-152
          aService de Néphrologie, et bLaboratoire d’Explorations Fonctionnelles Respiratoires, Hôpital Sainte Marguerite; cLaboratoire de Biophysique, Faculté de Pharmacie, Marseille, France; dUniversity of Rostock, FRG
          187792 Nephron 1994;66:147–152
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article